Moleculin Biotech, Inc. (MBRX)
| Market Cap | 10.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.82M |
| Shares Out | 2.23M |
| EPS (ttm) | -13.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,271 |
| Open | 5.150 |
| Previous Close | 4.840 |
| Day's Range | 4.610 - 5.290 |
| 52-Week Range | 0.338 - 6.240 |
| Beta | 1.85 |
| Analysts | Strong Buy |
| Price Target | 35.00 (+635.29%) |
| Earnings Date | May 10, 2024 |
About MBRX
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription fact... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for MBRX stock is "Strong Buy." The 12-month stock price forecast is $35.0, which is an increase of 635.29% from the latest price.
News
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
Patent, once issued, will provide composition protection through 2040, with potential for additional term extension Annamycin is advancing towards pivotal AML study in 2024 and may qualify for an acce...
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
HOUSTON , May 8, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin...
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13) Full MB-106 trial reaches 20 subjects with CRc of 45% in 1st – 7th line, wi...
Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
Live video webcast roundtable with members from the Moleculin Management Team and Dr. Tallman to discuss the unmet medical needs in the treatment of acute myeloid leukemia (AML), Annamycin and the Com...
Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
– Company appoints internationally renowned clinician, Martin S. Tallman, MD as inaugural clinician member HOUSTON, May 1, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin ...
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity FRENCHTOWN, NJ / ACCESSWIRE / April 25, 2024 / JTC Team ("JTC"), a ful...
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
– Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary CRc rate of 60% in 2nd line AML subject...
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
Annamycin demonstrated to be a more potent inhibitor of topoisomerase II-alpha and II-beta while remaining inactive against established cardiomyocyte cultures Results clearly aligned with lack of drug...
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
Live webcast on Thursday, April 4 th at 4:10 PM ET HOUSTON, March 28, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company ...
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Thursday, March 28 th at 12:00 PM ET HOUSTON , March 27, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Molecul...
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
Patent, once issued, will provide composition of matter protection through 2040, with potential for additional term extension Next-generation anthracycline uses unique lipid-based delivery technology ...
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
– Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 60% (50% CR) in 2nd line AML subjects – AnnAraC has potential to fill significant unmet need and expected to increase ...
Moleculin Reports Full Year 2023 Financial Results
– Year marked by growing body of positive Annamycin efficacy and safety clinical data expected to support advancement into a pivotal study for AML – Company to host conference call and webcast Mo...
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
In-depth discussion of stratification of Company's 2nd line data of Annamycin as a therapy for acute myeloid leukemia (AML) Guidance to be provided for clinical development strategy for advancement of...
Moleculin Announces Reverse Stock Split
HOUSTON , March 19, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clin...
Moleculin to Present at the 36th Annual ROTH Conference
Live webcast fireside chat on Monday, March 18 th at 9:00 AM PT HOUSTON , March 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceu...
Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
– MB-106 AML Phase 1B/2 trial (MB-106) preliminary data readout: Reached 67% recruitment – MB-106 preliminary results: Intent to Treat CR rate of 40% plus a CR/ CRi rate of 47% (N=15); Dosed Per Proto...
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
HOUSTON , Dec. 20, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h...
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting
- CR rate of 36% in Intent to Treat or ITT (n=11) subjects with durability - CR rate of 44% in subjects treated with Annamycin (n=9) - Durability of CR's up to 8 months & climbing (no relapses to date...
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
– MB-106: CR rate of 38% (N=8) with durability up to 8 months – Builds on CRi rate of 60% in MB-105 monotherapy AML trial last cohort (N=5) – MB-107: Phase 1B median extended over...
Moleculin Reports Third Quarter 2023 Financial Results
– Ends Quarter with $24.6 million in Cash with Runway Estimated into Third Quarter of 2024 – Third quarter marked by additional positive clinical data from Annamycin lead development programs – Growin...
Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast
HOUSTON , Nov. 7, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinic...
Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases
– Poster Presented at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting – Annamycin continues to be 100% non-cardiotoxic – Annamycin has Fast Track Status and Orphan Drug Designation f...
Moleculin to Participate in the Virtual Investor Ask the CEO Conference
Live video webcast with Walter Klemp, CEO and Jonathan Foster, Executive VP and CFO of Moleculin on Tuesday, October 25 th at 12:00 PM ET HOUSTON , Oct. 11, 2023 /PRNewswire/ -- Moleculin Biotech, Inc...
Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
– Phase 1B portion of Phase 1B/2 study demonstrated preliminary CR/CRi rate of 33% (n=6) – Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of AML HOUSTON , Oct. ...